Institut Merieux
17, Rue Bourgelat
Lyon, France

Attention: Dr. Charles Merieux, President
Dr. Dubreuil, Pharmacien-Gerant

Dear Doctor Merieux,

In accord with your letter of 3 October, 1960, in which you indicated the decision of the Institut Merieux to produce live, attenuated poliovirus vaccine from my strains, I should like to say that I shall be glad to make available to your institute portions of the original field-tested lots of vaccine on the same conditions that it has already been made available to various pharmaceutical organizations in the United States, Canada, and Europe. These conditions are:

1) The vaccine will be produced in a separate facility in which no other infectious agents or tissue culture cell lines, other than those employed in the production of the vaccine, will be used. The definition of a separate facility will conform to that set down by the Division of Biologics Standards of the National Institutes of Health of the United States. It is understood that the premises will be suitably sterilized prior to beginning of production.

2) Personnel while working in poliovirus vaccine manufacturing areas may not work with other infectious agents in any other laboratory and return to the live poliovirus production area during the same working day. This means that they can work in the vaccine manufacturing area during the morning and in some other area in the afternoon of the same day, and in the next day return to the polio vaccine manufacturing area - but that they cannot work with other infectious agents in the morning and in the polio vaccine production area in the afternoon of the same day.
3) The recommended procedures for production, testing and assay, which I shall supply, will be followed except as they may be specifically extended by the requirements of an official governmental agency in France.

4) The certification mark "SABIN" will appear on the labels carried by the containers of the vaccine and will be applied to the packages in which the containers are shipped. Depending on the contents of the containers, the labels will carry the following information:

Oral poliovirus vaccine, Type 1 (Sabin)
" " " , Type 2 ( )
" " " , Type 3 ( )
" " " , Types 1+2+3 (Sabin)

This provision is not intended to prevent your company from using your own specific trade mark on the labels in addition to the above.

5) The three strains, representing each of the three types of poliovirus, shall be used separately or as a mixture of all three types, in accordance with the recommendations to be approved by me. There shall be no substitution of another strain for any of the three types that I have supplied except by prior agreement between the manufacturer and myself, or upon approval of the United States Public Health Service.

6) Your institute agrees that in return for supplying the seed strains, the directions for production and testing, and authorization to use the name "SABIN" on the label of its product, that it will manufacture this product in strict accordance with the terms and conditions agreed upon by and between your institute and myself, as described in the preceding paragraphs 1, 2, 3, 4 and 5, and that your institute will permit me from time to time, upon request, to examine a sample of the product, the protocols of production and testing, and the histologic sections of the monkeys used in the neurovirulence tests.
If you find these conditions agreeable I would appreciate it very much if the responsible officers of your institute would sign the copy of this letter enclosed herewith, in the space provided therefor. Upon receipt of the signed copy I will send you 50 ml. of each of the 3 strains, and a copy of the directions for the preparation, testing and assay of the vaccine.

With best wishes.

Sincerely yours,

Albert B. Sabin, M. D.

ACCEP TED AND AGREED TO:

DATE:

COMPANY: Institut Merieux Lyon, France

AUTHORIZED OFFICER:

Charles Merieux, President

Dubreuil, Pharmacien-Gerant